Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product R&D

Tempest takes PPAR alpha into cancer

Why Tempest thinks PPARα could succeed in cancer where IDO failed

Lauren Martz, Senior Writer
November 15, 2018 10:55 PM UTC

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer.

Tapping into the emerging field of cancer immuno-metabolism, Tempest is moving beyond IDO with a target that acts via a different mechanism and controls cancer cells in addition to immune cells. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Tempest Therapeutics Inc.